These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18448571)

  • 41. Metabolism of cyadox in rat, chicken and pig liver microsomes and identification of metabolites by accurate mass measurements using electrospray ionization hybrid ion trap/time-of-flight mass spectrometry.
    Liu Z; Huang L; Dai M; Chen D; Tao Y; Wang Y; Yuan Z
    Rapid Commun Mass Spectrom; 2009 Jul; 23(13):2026-34. PubMed ID: 19504544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo investigation of metabolic fate of rifampicin using an optimized sample preparation approach and modern tools of liquid chromatography-mass spectrometry.
    Prasad B; Singh S
    J Pharm Biomed Anal; 2009 Oct; 50(3):475-90. PubMed ID: 19535209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo phase II metabolism of combretastatin A-4: evidence for the formation of a sulphate conjugate metabolite.
    Aprile S; Del Grosso E; Grosa G
    Xenobiotica; 2009 Feb; 39(2):148-61. PubMed ID: 19255941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity.
    Sedrani R; Jones LH; Jutzi-Eme AM; Schuler W; Cottens S
    Bioorg Med Chem Lett; 1999 Feb; 9(3):459-62. PubMed ID: 10091702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
    Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H
    Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques.
    Jung J; Meyer MR; Maurer HH; Neusüss C; Weinmann W; Auwärter V
    J Mass Spectrom; 2009 Oct; 44(10):1423-33. PubMed ID: 19728318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp.
    Laplante A; Demeule M; Murphy GF; Béliveau R
    Transplant Proc; 2002 Dec; 34(8):3393-5. PubMed ID: 12493480
    [No Abstract]   [Full Text] [Related]  

  • 50. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
    Seckinger J; Sommerer C; Hinkel UP; Hoffmann O; Zeier M; Schwenger V
    J Hypertens; 2008 Nov; 26(11):2213-9. PubMed ID: 18854763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
    Chu C; Abbara C; Noël-Hudson MS; Thomas-Bourgneuf L; Gonin P; Farinotti R; Bonhomme-Faivre L
    Biochem Pharmacol; 2009 May; 77(10):1629-34. PubMed ID: 19426700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option.
    Yoon KH
    Ann N Y Acad Sci; 2009 Sep; 1173():752-6. PubMed ID: 19758225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sirolimus-induced aphthous ulcers which disappeared with conversion to everolimus.
    Ram R; Swarnalatha G; Neela P; Dakshinamurty KV
    Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):819-20. PubMed ID: 18711306
    [No Abstract]   [Full Text] [Related]  

  • 55. Identification of stereoisomeric metabolites of meisoindigo in rat liver microsomes by achiral and chiral liquid chromatography/tandem mass spectrometry.
    Huang M; Goh LT; Ho PC
    Drug Metab Dispos; 2008 Nov; 36(11):2171-84. PubMed ID: 18710897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of metabolites of meisoindigo in rat, pig and human liver microsomes by UFLC-MS/MS.
    Huang M; Ho PC
    Biochem Pharmacol; 2009 Apr; 77(8):1418-28. PubMed ID: 19426681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
    Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
    Prakash C; Wang W; O'Connell T; Johnson KA
    Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of metabolites of meisoindigo in male and female rat kidney microsomes by high-performance liquid chromatography coupled with positive electrospray ionization tandem mass spectrometry.
    Huang M; Choo LW; Ho PC
    Rapid Commun Mass Spectrom; 2008 Dec; 22(23):3835-45. PubMed ID: 18980268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.
    Prakash C; Johnson KA; Schroeder CM; Potchoiba MJ
    Drug Metab Dispos; 2008 Sep; 36(9):1753-69. PubMed ID: 18515329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.